Benjamin F. Edwards & Company Inc. Acquires 6,989 Shares of Sanofi (NASDAQ:SNY)

Benjamin F. Edwards & Company Inc. raised its holdings in shares of Sanofi (NASDAQ:SNY) by 314.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,210 shares of the company’s stock after purchasing an additional 6,989 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Sanofi were worth $458,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Cardinal Capital Management grew its stake in Sanofi by 0.3% in the fourth quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock valued at $2,927,000 after purchasing an additional 201 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Sanofi by 3.4% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock valued at $325,000 after acquiring an additional 216 shares in the last quarter. Gallacher Capital Management LLC raised its position in shares of Sanofi by 4.5% in the 3rd quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock valued at $307,000 after purchasing an additional 245 shares during the last quarter. Rise Advisors LLC boosted its stake in Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares in the last quarter. Finally, True Wealth Design LLC grew its position in Sanofi by 1.9% during the 3rd quarter. True Wealth Design LLC now owns 13,828 shares of the company’s stock worth $742,000 after purchasing an additional 260 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on SNY. Morgan Stanley started coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective for the company. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Sanofi Stock Up 1.1 %

SNY opened at $50.10 on Thursday. The company has a market cap of $126.73 billion, a PE ratio of 25.18, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.72. The company has a 50-day moving average price of $47.95 and a 200 day moving average price of $48.12.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a dividend of $1.478 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is 69.35%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.